Nevirapine 

The Ministry of Health’s Drug Advisory Committee has recommended the following antiretroviral therapies (ARTs):

• Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): lamivudine 150 mg tablet, tenofovir disoproxil fumarate 300 mg tablet, zidovudine 100 mg capsule;
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz 200 mg and 600 mg tablets, etravirine 200 mg tablet, nevirapine 200 mg and 400 mg tablets, rilpivirine 25 mg tablet;
• Protease inhibitors (PIs): atazanavir 200 mg and 300 mg capsules, darunavir 600 mg and 800 mg tablets, lopinavir 200 mg/ritonavir 50 mg tablet and lopinavir 80 mg/ritonavir 20 mg oral solution, ritonavir 100 mg tablet;
• Integrase strand transfer inhibitors (INSTIs): dolutegravir 50 mg tablet, raltegravir 400 mg and 600 mg tablets; and
• Fixed-dose combinations: abacavir 600 mg/lamivudine 300 mg tablet, abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg tablet, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet

in line with their registered indications for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.

Subsidy status